Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   42314   clinical trials with a EudraCT protocol, of which   6969   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).


    Phase 1 trials conducted solely in adults and that are not part of an agreed PIP are not public in the EU CTR (refer to European Guidance 2008/C 168/02   Art. 3 par. 2 and   Commission Guideline 2012/C 302/03,   Art. 5) .

    Clinical Trials marked as "Trial now transitioned" were transitioned to the Clinical Trial Regulation 536/2014 and can be further followed in the Clinical Trial Information System  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-001163-37
    Sponsor's Protocol Code Number:CNTO1959PSA3001
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2017-06-21
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-001163-37
    A.3Full title of the trial
    A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Subjects with Active Psoriatic Arthritis including those Previously Treated with Biologic Anti-TNFα Agent(s)
    Ensayo clínico multicéntrico en fase 3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de guselkumab administrado por vía subcutánea en pacientes con artritis psoriásica activa, incluidos pacientes previamente tratados con agentes biológicos anti-TNFα.
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Phase 3 Study of Guselkumab in Subjects with Active Psoriatic Arthritis
    Ensayo clínico en fase 3 de Guselkumab en pacientes con Artritis Psoriásica activa.
    A.3.2Name or abbreviated title of the trial where available
    Discover-1
    A.4.1Sponsor's protocol code numberCNTO1959PSA3001
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorJanssen-Cilag International N.V.
    B.1.3.4CountryBelgium
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportJanssen Research & Development, LLC
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationJanssen-Cilag S.A
    B.5.2Functional name of contact pointGlobal Clinical Operations Spain
    B.5.3 Address:
    B.5.3.1Street AddressPaseo de las Doce Estrellas, 5-7
    B.5.3.2Town/ cityMadrid
    B.5.3.3Post code28042
    B.5.3.4CountrySpain
    B.5.4Telephone number+3491722 8100
    B.5.5Fax number+3491722 8628
    B.5.6E-mailagonza45@its.jnj.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGuselkumab
    D.3.2Product code CNTO1959
    D.3.4Pharmaceutical form Solution for injection in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGuselkumab
    D.3.9.2Current sponsor codeCNTO1959
    D.3.9.3Other descriptive nameGUSELKUMAB
    D.3.9.4EV Substance CodeSUB179789
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number100
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy Yes
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product Yes
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product Yes
    D.3.11.13.1Other medicinal product typeMonoclonal antibody
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboSolution for injection in pre-filled syringe
    D.8.4Route of administration of the placeboSubcutaneous use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Active Psoriatic Arthritis
    Artritis Psoriásica Activa
    E.1.1.1Medical condition in easily understood language
    Active Psoriatic Arthritis
    Artritis Psoriásica Activa
    E.1.1.2Therapeutic area Diseases [C] - Nervous System Diseases [C10]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10037160
    E.1.2Term Psoriatic arthritis
    E.1.2System Organ Class 100000004859
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to evaluate the efficacy of guselkumab treatment in subjects with active PsA by assessing the reduction in signs and symptoms of PsA.
    El objetivo principal de este estudio es evaluar la eficacia del tratamiento con guselkumab en pacientes con artritis psoriásica (APs) activa valorando la reducción de signos y síntomas de APs.
    E.2.2Secondary objectives of the trial
    - Efficacy in improving psoriatic skin lesions
    - Improvement in physical function
    - Efficacy in improving general and disease specific health-related quality of life and patient-reported health outcomes
    - Safety
    - Pharmacokinetics, PD, and immunogenicity
    - Eficacia para mejorar las lesiones cutáneas psoriásicas.
    - Mejoría de la funcionalidad física.
    - Eficacia para mejorar la calidad de vida relacionada con la salud general y específica de la enfermedad y los resultados de salud comunicados por los pacientes.
    - Seguridad.
    - Farmacocinética, farmacodinámica e inmunogenicidad.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Be a man or a woman at least 18 years of age
    2. Have a diagnosis of PsA for at least 6 months before the first administration of study agent and meet ClASsification criteria for Psoriatic ARthritis at screening
    3. Have active PsA as defined by:
    a. At least 3 swollen joints and at least 3 tender joints at screening and at baseline
    -AND-
    b. C-reactive protein (CRP) ≥0.3 mg/dL at screening from the central laboratory.
    4. Have at least 1 of the PsA subsets: distal interphalangeal joint involvement, polyarticular arthritis with absence of rheumatoid nodules, arthritis mutilans, asymmetric peripheral arthritis, or spondylitis with peripheral arthritis
    5. Have active plaque psoriasis, with at least one psoriatic plaque of ≥2cm diameter or nail changes consistent with psoriasis or documented history of plaque psoriasis.
    6. Have active PsA despite previous non-biologic DMARD, apremilast, and/or NSAID therapy.
    - Non-biologic DMARD therapy is defined as taking a non-biologic DMARD for at least 3 months or evidence of intolerance.
    - Apremilast therapy is defined as taking apremilast at the marketed dose approved in the country where the study is being conducted for at least 4 months or evidence of intolerance.
    - NSAID therapy is defined as taking an NSAID for at least 4 weeks or evidence of intolerance.
    7. Subjects may have been previously treated with up to 2 anti-TNFα agents , and must document the reason for discontinuation
    a. Lack of benefit to an anti-TNFα therapy, as assessed by the treating physician, after at least 12 weeks of etanercept, adalimumab, golimumab, or certolizumab pegol therapy and/or at least a 14 week dosage regimen of infliximab. Documented lack of benefit may include inadequate improvement in joint counts, physical function, or disease activity.
    b. Intolerance to an anti-TNFα biologic therapy, as assessed by the treating physician, to etanercept, adalimumab, golimumab, certolizumab pegol, or infliximab.
    c. If no intolerance or lack of benefit, the reason for discontinuation must be documented.
    8. If currently using non-biologic DMARDs subjects should have started treatment at least 3 months and the dose must be stable for at least 4 weeks before first administration of study agent and should have no serious toxic side effects attributable to the non-biologic DMARD. If currently not using a MTX, SSZ, or HCQ, must have not received for at least 4 weeks before first administration of study agent.
    If currently not using LEF, must not have received for at least 12 weeks before first administration of study agent.
    a) If using MTX, the route of administration and dose must be stable and the dose must be ≤25 mg/week.
    b) If receiving SSZ, the dose must be ≤ 3g/day.
    c) If receiving HCQ, the dose must be ≤400 mg/day.
    d) If receiving LEF, the dose must be ≤20 mg/day.
    9. If currently using NSAIDs or other analgesics for PsA, subjects must be on a stable dose for at least 2 weeks before first administration of study agent. If currently not using NSAIDs or other analgesics for PsA, must not have received NSAIDs or other analgesics for PsA within 2 weeks before first administration of study agent.
    10. If currently using oral corticosteroids for PSA, subjects must be on a stable dose equivalent to ≤10 mg of prednisone/day for at least 2 weeks before first administration of study agent.
    If currently not using oral corticosteroids, the subject must not have received oral corticosteroids within 2 weeks before first administration of study agent

    For a complete overview of the inclusion criteria please refer to protocol section 4.1. (pages 45-49)
    1. Ser varón o mujer mayor de 18 años.
    2. Haber sido diagnosticado de APs al menos 6 meses antes de la primera administración del fármaco de estudio y cumplir con los Criterios de Clasificación para Artritis Psoriásica (CASPAR) en la selección.
    3. Presentar APs activa de acuerdo con la siguiente deficinión:
    a. Al menos 3 articulaciones inflamadas y al menos 3 articulaciones dolorosas en la selección y en la visita basal.
    -Y-
    b. Niveles de proteína C reactiva (CRP) ≥0.3 mg/dL en los resultados de laboratorio central en la selección.
    4. Presentar al menos 1 de los subtipos de APs: implicación de las articulaciones interfalangicas distales, artiritis poliarticular con ausencia de nódulos reumatoides, artritis mutilante, artritis periférica asimétrica o espondilitis con artritis periférica.
    5. Presentar placas activas de psoriasis, con al menos una placa de ≥2cm de diámetro o cambios en las uñas consistentes con psoriasis o historia documentada de psoriasis en placas.
    6. Presentar APs activa a pesar de terapia previa con DMARDs no-biológicos, apremilast y/o AINEs.
    - La terapia con DMARDs no-biológicos se define como tomar DMARDs no-biológicos durante al menos 3 meses o evidencia de intolerancia.
    - La terapia con apremilast se define como tomar apremilast a la dosis marcada aprobada en el país dónde se esté llevando a cabo el estudio durante al menos 4 meses o evidencia de intolerancia.
    - la terapia con AINEs se define como tomar AINEs durante al menos 4 semanas o evidencia de intolerancia.
    7. Los sujetos puede haber recibido anteriormente tratamiento con agentes anti-TNFα, la razón por la que se interrumpió dicha terapia debe estar documentada.
    a. Falta de beneficio a la terapia anti-TNFα, valorada por el médico que le trata, después de al menos 12 semanas de terapia con etanercept, adalimumab, golimumab, o certolizumab pegol y/o al menos 14 semanas de régimen de dosificación con infliximab. La falta de beneficio documentada puede incluir la inadecuada mejora de recuento de articulationes, función física o actividad de la enfermedad.
    b. Intolerancia a la terapia con anti-TNFα biológicos, valorada por el médico que le trata, a etanercept, adalimumab, golimumab, certolizumab pegol, o infliximab.
    c. Si no ha presentado intolerancia o falta de beneficio, el motivo de la discontinuación debe estar documentado.
    8. Si está recibiendo DMARDs no-biológicos, debe haber estado tratándose al menos 3 meses y a dosis estable al menos durante 4 semanas antes de la primera administración del fármaco del estudio y no deben presentar efectos secundarios serios tóxicos atribuibles a los DMARDs no-biológicos. Si actualmente no recibe MTX, SSZ o HCQ, no debe haberlos recibido durante al menos 4 semanas antes de la primera administración del fármaco del estudio.
    Si actualmente no recibe LEF, no debe haberlo recibido al menos durante las 12 semanas previas a la primera administración del fármaco del estudio.
    a. Si toma MTX, la ruta de administración y la dosis debe mantenerse estable y a ≤25 mg/semana.
    b. Si recibe SSZ, la dosis debe ser ≤ 3g/día.
    c. Si recibe HCQ la dosis debe ser ≤400 mg/día.
    d. Si recibe LEF, la dosis debe ser ≤20 mg/día.
    9. Si actualmente está tomando AINEs u otros analgésicos para la APs, la dosis debe mantenerse estable durante al menos 2 semanas antes de la primera administración de fármaco de estudio. Si actualmente no está tomando AINEs u otros analgésicos para APs, no debe haber recibido AINEs u otros analgésicos para APs durante las 2 semanas previas a la primera administración de fármaco del estudio.
    10. Si actualmente está tomando coricosteroides orales para APs, debe mantenerse a una dosis estable equivalente a prednisona ≤10 mg/día durante al menos dos semanas antes de la primera administración del fármaco del estudio.
    Si actualmente no está tomando corticosteroides orales, el paciente no debe haber recibido corticosteroides orales dentro de las 2 semanas previas a la primera administración del fármaco del estudio.
    Para consultar los criterios de inclusión adicionales, por favor consulte la sección 4.1 de protocolo (páginas 45-49).
    E.4Principal exclusion criteria
    1. Has other inflammatory diseases that might confound the evaluations of benefit of guselkumab therapy, including but not limited to RA, axial spondyloarthritis, systemic lupus erythematosus, or
    Lyme disease.
    2. Has ever received more than 2 anti-TNFα agents.
    3. Has received an anti-TNF agent within the following timeframes:
    a. Has received infliximab or golimumab within 8 weeks before the first administration of study agent.
    b. Has received golimumab SC, adalimumab or certolizumab pegol within 6 weeks before the first administration of study agent.
    c. Has received etanercept within 4 weeks before the first administration of study agent.
    4. Has previously been treated with guselkumab.
    5. Has previously received any biologic treatment (other than anti-TNFα agents), including, but not limited to ustekinumab, abatacept, secukinumab, tildrakizumab, ixekizumab, brodalumab, risankizumab, or other investigative biologic treatment.
    6. Has previously received tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib, or any other Janus kinase inhibitor.
    7. Has previously received any systemic immunosuppressants
    8. Has received non-biologic DMARDs including, but not limited to chloroquine, gold preparations, and penicillamine within 4 weeks before the first administration of study agent.
    9. Is currently receiving 2 or more non-biologic DMARDs at baseline.
    10. Has received apremilast within 4 weeks prior to the first administration of study agent.

    For a complete overview of the exclusion criteria please refer to protocol section 4.2. (pages 49-52)
    1. Presentar otra enfermedad inflamatoria que pueda dar lugar a confusión en las evaluaciones o beneficios de la terapia con guselkumab incluyendo, pero no solamente, AR, espondiloartritis axial, lupus eritematoso sistémico o enfermedad de Lyme.
    2. Haber recibido más de 2 agentes anti-TNFα.
    3. Haber recibido un agente anti-TNFα dentro de los siguientes periodos de tiempo:
    a. Haber recibido infliximab o golimumab durante las 8 semanas previas a la primera administración de fármaco del estudio.
    b. Haber recibido golimumab SC, adalimumab o certolizumab pegol durante las 6 semanas previas a la primera administración de fármaco del estudio.
    c. Haber recibido etanercept durante las 4 semanas previas a la primera administración de fármaco del estudio.
    4. Haber recibido previamente tratamiento con guselkumab.
    5. Haber recibido previamente algún tratamiento biológico (que no sea un agente anti-TNFα) incluyendo, pero no limitado a, ustekinumab, abatacept, secukinumab, tildrakinumab, ixekinumab, brodalumab, risakizumab u otros tratamientos biológicos en investigación.
    6. Haber recibido previamente tofacitinib, baricitinib, filgotinib, peficitinib, decernotinib o algún otro inhibidor de la kinasa Janus.
    7. Haber recibido algún inmunosupresor sistémico.
    8 Haber recibido DMARDs no-biológicos incluyendo, pero no limitado a, cloroquina, preparaciones de oro, y penicilamina durante las 4 semanas previas a la primera administración de fármaco del estudio.
    9. Estar recibiendo actualmente 2 o más DMARDs no-biológicos en el momento basal.
    10. Haber recibido apremilast durante las 4 semanas previas a la primera administración de fármaco del estudio.
    Para una visión completa de los criterios de exclusión, refiérase al apartado 4.2. del protocolo (páginas 49-52).
    E.5 End points
    E.5.1Primary end point(s)
    The proportion of subjects who achieve an ACR 20 response at Week 24
    Proporción de pacientes que logran una respuesta del American College of Rheumatology (ACR) 20 en la semana 24
    E.5.1.1Timepoint(s) of evaluation of this end point
    Week 24
    Semana 24
    E.5.2Secondary end point(s)
    1. Change from baseline in HAQ-DI score at Week 24.
    2. Proportion of subjects who achieve an ACR 50 response at Week 24.
    3. Proportion of subjects with a psoriasis response of an Investigator Global Assessment at Week 24 among subjects with ≥3% body surface area psoriatic involvement and an IGA score of ≥2 at baseline.
    4. Proportion of subjects who achieve an ACR 20 response at Week 16.
    5. Change from baseline in DAS28 at Week 24.
    6. Proportion of subjects who achieve an ACR 70 response at Week 24.
    7. Proportion of subjects who achieve an ACR 50 response at Week 16.
    8. Change from baseline in 36-item short form health survey (SF-36) Physical Component Summary at Week 24.
    9. Proportion of subjects with resolution of enthesitis at Week 24 among the subjects with enthesitis at baseline.
    10. Change from baseline in enthesitis score at Week 24 among the subjects with enthesitis at baseline.
    11. Change from baseline in SF-36 Mental Component Summary at Week 24.
    12. Proportion of subjects with resolution of dactylitis at Week 24 among the subjects with dactylitis at baseline.
    13. Change from baseline in dactylitis scores at Week 24 among the subjects with dactylitis at baseline.

    For additional secondary endpoints please refer to the protocol, section 2.1
    1. Variación con respecto al momento basal de la puntuación en el cuestionario de evaluación de la salud-índice de discapacidad (HAQ-DI) en la semana 24.
    2. Proporción de pacientes que logran una respuesta ACR 50 en la semana 24.
    3. Proporción de pacientes que logran una respuesta de la psoriasis según la evaluación global por el investigador (IGA) (es decir, una puntuación IGA de la psoriasis de 0 [remisión completa] o 1 [mínima] Y una reducción de ≥ 2 grados respecto al valor basal) en la semana 24 entre los pacientes con BSA ≥ 3 % y una puntuación IGA ≥ 2 (leve) en el momento basal.
    4. Proporción de pacientes que logran una respuesta ACR 20 en la semana 16.
    5. Variación con respecto al momento basal en la DAS28 (proteína C reactiva [CRP]) en la semana 24.
    6. Proporción de pacientes que logran una respuesta ACR 70 en la semana 24.
    7. Proporción de pacientes que logran una respuesta ACR 50 en la semana 16.
    8. Variación con respecto al momento basal en el resumen de componentes físicos (PCS) del cuestionario de salud abreviado de 36 preguntas (SF-36) en la semana 24.
    9. Proporción de pacientes con resolución de la entesitis en la semana 24, en relación al total de pacientes que presentaban entesitis en el momento basal.
    10. Variación con respecto al momento basal de la puntuación de la entesitis (basado en el índice de entesitis de Leeds [LEI]) en la semana 24, en relación al total de pacientes que presentaban entesitis en el momento basal.
    11. Variación con respecto al momento basal del resumen de componentes mentales (MCS) del SF-36 en la semana 24.
    12. Proporción de pacientes con resolución de la dactilitis en la semana 24, en relación al total de pacientes que presentaban dactilitis en el momento basal.
    13. Variación con respecto al momento basal de la puntuación de la dactilitis en la semana 24, en relación al total de pacientes que presentaban dactilitis en el momento basal.

    Para ver los criterios de valoración secundarios adicionales, refiérase a la sección 2.1 del protocolo.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1 - 3, 5 - 6, 8 - 13: Week 24
    4, 7: Week 16
    1-3, 5-6, 8-13: Semana 24
    4, 7: Semana 16
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned9
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA56
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Canada
    Czech Republic
    Germany
    Hungary
    Korea, Republic of
    Malaysia
    Poland
    Russian Federation
    Spain
    Taiwan
    Ukraine
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    Última visita del último paciente
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months10
    E.8.9.1In the Member State concerned days29
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months10
    E.8.9.2In all countries concerned by the trial days29
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 288
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 72
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state25
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 250
    F.4.2.2In the whole clinical trial 360
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    There are no plans for additional treatment or care after the subject ends (or has ended) participation in the trial.
    No está planeado el tratamiento adicional o cuidado después de que el paciente finalice (o haya finalizado) la participación en el ensayo.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-08-02
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-06-21
    P. End of Trial
    P.End of Trial StatusCompleted
    P.Date of the global end of the trial2019-11-14
    For support, visit the EMA Service Desk , log in using your EMA account and open a ticket specifying "EU CTR" in your request.
    If you do not have an account, please visit the EMA Account management page page click on "Create an EMA account" and follow the instructions.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2022 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA